UroGen Pharma (URGN) Operating Income (2016 - 2025)
Historic Operating Income for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$27.4 million.
- UroGen Pharma's Operating Income fell 5609.01% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$133.4 million, marking a year-over-year decrease of 5932.31%. This contributed to the annual value of -$96.8 million for FY2024, which is 4767.76% down from last year.
- Latest data reveals that UroGen Pharma reported Operating Income of -$27.4 million as of Q3 2025, which was down 5609.01% from -$41.4 million recorded in Q2 2025.
- UroGen Pharma's 5-year Operating Income high stood at -$13.5 million for Q3 2023, and its period low was -$41.4 million during Q2 2025.
- Its 5-year average for Operating Income is -$23.1 million, with a median of -$22.0 million in 2023.
- As far as peak fluctuations go, UroGen Pharma's Operating Income surged by 2822.96% in 2021, and later crashed by 8932.17% in 2024.
- UroGen Pharma's Operating Income (Quarter) stood at -$19.9 million in 2021, then fell by 1.84% to -$20.3 million in 2022, then grew by 27.97% to -$14.6 million in 2023, then tumbled by 89.32% to -$27.7 million in 2024, then rose by 0.98% to -$27.4 million in 2025.
- Its Operating Income was -$27.4 million in Q3 2025, compared to -$41.4 million in Q2 2025 and -$36.9 million in Q1 2025.